[8-K] Genprex, Inc. Reports Material Event

Rhea-AI Filing Summary

Genprex, Inc. reports that a Nasdaq Hearings Panel has determined the company has regained compliance with Nasdaq’s $1.00 minimum bid price requirement. The Panel also approved an exception giving Genprex until December 31, 2025 to demonstrate long-term compliance with the Nasdaq stockholders’ equity requirement, with the possibility of further extension to February 9, 2026 at the Panel’s discretion.

The Panel may reconsider this exception if new events make continued listing inadvisable, and there is no assurance of any extension beyond December 31, 2025. Genprex states it believes it will need to complete additional capital raising transactions to regain compliance with the stockholders’ equity requirement, and notes there is no guarantee such financing will be available on acceptable terms, or at all.

Positive

• None.

Negative

• Ongoing Nasdaq equity deficiency and financing uncertainty: Genprex remains reliant on a Nasdaq exception until December 31, 2025 to meet the stockholders’ equity requirement and believes it must raise additional capital, while stating there is no guarantee such financing will be available on acceptable terms, or at all.

Insights

Equity listing and capital markets analyst

Genprex regains Nasdaq bid-price compliance but still faces equity and financing risks.

Genprex has resolved its immediate Nasdaq bid-price deficiency, with the Panel confirming compliance with the $1.00 minimum bid rule. However, the company remains under an exception until December 31, 2025 to prove sustained compliance with Nasdaq’s stockholders’ equity requirement, and any extension toward February 9, 2026 is entirely at the Panel’s discretion.

The company explicitly states it believes it will need additional capital raising transactions to meet the stockholders’ equity standard, while acknowledging there is no guarantee that such financing will be available on acceptable terms, or at all. This highlights ongoing dilution and funding risk alongside the possibility that the Panel could reconsider the exception if new adverse events occur.

Overall, the update removes one acute trigger for delisting tied to bid price but keeps attention on equity levels, successful capital formation, and future Nasdaq determinations under the current exception window.

false 0001595248 0001595248 2025-11-25 2025-11-25

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

November 25, 2025

Date of report (Date of earliest event reported)

GENPREX, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-38244	90-0772347
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification Number)
3300 Bee Cave Road, #650-227, Austin, TX		78746
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (512) 537-7997

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		GNPX		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously disclosed, the Nasdaq Hearings Panel (the “Panel”) of the Nasdaq Stock Market, LLC (“Nasdaq”) had previously notified the Company on October 13, 2025 that the Panel had granted the Company’s request for an exception to demonstrate compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”) and the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market, under Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Requirement”) for continued listing through October 31, 2025.

On November 25, 2025, the Company was formally notified that (i) the Panel determined that the Company has regained compliance with the Bid Price Requirement; and (ii) the Panel has also approved the Company’s request for an exception until December 31, 2025 to demonstrate long-term compliance with the Stockholders’ Equity Requirement (as extended, the “Exception”).

As previously disclosed, upon request by the Company, the Panel has discretion to grant the Company continued listing through February 9, 2026.  Pursuant to the Exception, the Company is required to, and fully intends to, provide the Panel with prompt notification of any significant events that occur, including any event that may call into question the Company’s ability to satisfy the terms of the Exception. If such events do occur, the Company may request a further extension beyond December 31, 2025 to regain compliance with the Stockholders’ Equity Requirement. The Panel has reserved the right to reconsider the terms of the Exception based on any event, condition or circumstance that exists or develops that would, in the Panel’s opinion, make continued listing of the Company’s securities on Nasdaq inadvisable or unwarranted.  There can be no assurance that the Panel would exercise their discretion to grant an extension beyond December 31, 2025.

The Company believes it will need to engage in additional capital raising transactions to regain compliance with the Stockholders’ Equity Requirement, and there is no guarantee that such financing will be available on terms acceptable to the Company, or at all. 

Cautionary Language Concerning Forward-Looking Statements

This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act, as amended, including those relating to the Company’s ability to regain (as applicable) and maintain compliance with the continued listing requirements of Nasdaq and maintain the listing of the Company’s common stock; statements about the future listing of the Company’s common stock; statements about the Company’s intentions and plans for addressing Nasdaq listing deficiencies, including statements about plans for regaining compliance and intended actions following the Nasdaq Panel hearing and Panel decision; and statements about the Company’s intentions and plans including anticipated actions and requests in connection with the Nasdaq process, requests for further extensions, statements about requested relief from Nasdaq or the hearing Panel or the type of relief that may be available; statements regarding plans that the Company may implement or actions that the Company may take in furtherance of regaining compliance; statements about the Company’s ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines; and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which the Company operates and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential, “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or the Company’s financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in “Risk Factors” in the Company’s most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2024, the Company’s Quarterly Reports on Form 10-Q filed since such Annual Report on Form 10-K, and the Company’s other filings from time to time with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	GENPREX, INC.
Date: November 26, 2025	By:	/s/ Ryan Confer
		Ryan Confer
		President, Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer)

FAQ

What did Genprex, Inc. (GNPX) announce regarding its Nasdaq listing?

Genprex reported that a Nasdaq Hearings Panel determined the company has regained compliance with the $1.00 minimum bid price requirement and granted an exception until December 31, 2025 to demonstrate long-term compliance with the stockholders’ equity requirement.

Is Genprex now fully compliant with all Nasdaq continued listing requirements?

Genprex is compliant with the minimum bid price rule, but continues under an exception related to the stockholders’ equity requirement, which it must satisfy by December 31, 2025 to demonstrate long-term compliance.

How long is Genprex’s Nasdaq stockholders’ equity exception in place?

The Nasdaq Panel approved an exception giving Genprex until December 31, 2025 to show long-term compliance with the stockholders’ equity requirement, with potential, but not assured, continued listing through February 9, 2026 at the Panel’s discretion.

What risks did Genprex highlight about its ability to maintain its Nasdaq listing?

Genprex noted that the Panel can reconsider the exception if new events make continued listing inadvisable and stated there is no assurance the Panel will grant an extension beyond December 31, 2025.

Does Genprex expect to raise capital to meet Nasdaq’s stockholders’ equity requirement?

Yes. Genprex stated it believes it will need to engage in additional capital raising transactions to regain compliance with the stockholders’ equity requirement, and cautioned there is no guarantee such financing will be available on acceptable terms, or at all.

What forward-looking statements did Genprex include in this 8-K?

Genprex included forward-looking statements about its ability to regain and maintain Nasdaq listing compliance, its intentions and plans to address Nasdaq deficiencies and seek extensions, and its ability to advance development, manufacturing and commercialization of its product candidates.